Financhill
Sell
36

COR Quote, Financials, Valuation and Earnings

Last price:
$360.89
Seasonality move :
2.16%
Day range:
$356.24 - $361.19
52-week range:
$240.72 - $377.54
Dividend yield:
0.64%
P/E ratio:
43.43x
P/S ratio:
0.22x
P/B ratio:
36.81x
Volume:
1.1M
Avg. volume:
1.3M
1-year change:
48.31%
Market cap:
$70.2B
Revenue:
$321.3B
EPS (TTM):
$8.31

Analysts' Opinion

  • Consensus Rating
    Cencora, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 10 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $403.79, Cencora, Inc. has an estimated upside of 11.83% from its current price of $361.08.
  • Price Target Downside
    According to analysts, the lowest downside price target is $340.00 representing 100% downside risk from its current price of $361.08.

Fair Value

  • According to the consensus of 13 analysts, Cencora, Inc. has 11.83% upside to fair value with a price target of $403.79 per share.

COR vs. S&P 500

  • Over the past 5 trading days, Cencora, Inc. has overperformed the S&P 500 by 1.93% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Cencora, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Cencora, Inc. has grown year-over-year revenues for 53 quarters straight. In the most recent quarter Cencora, Inc. reported revenues of $85.9B.

Earnings Growth

  • Cencora, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Cencora, Inc. reported earnings per share of $2.87.
Enterprise value:
76.5B
EV / Invested capital:
--
Price / LTM sales:
0.22x
EV / EBIT:
19.83x
EV / Revenue:
0.24x
PEG ratio (5yr expected):
2.38x
EV / Free cash flow:
21.22x
Price / Operating cash flow:
19.51x
Enterprise value / EBITDA:
15.62x
Gross Profit (TTM):
$10.7B
Return On Assets:
2.22%
Net Income Margin (TTM):
0.5%
Return On Equity:
107.99%
Return On Invested Capital:
16.71%
Operating Margin:
1.17%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Income Statement
Revenue $271.6B $303.2B $325.8B $81.5B $85.9B
Gross Profit $8B $8.8B $10.7B $2.3B $2.8B
Operating Income $2.6B $3B $3.9B $791.8M $1B
EBITDA $3.6B $4.2B $4.9B $1.1B $1.3B
Diluted EPS $9.18 $7.03 $8.31 $2.50 $2.87
Period Ending 2021-12-31 2022-12-31 2023-12-31 2024-12-31 2025-12-31
Balance Sheet
Current Assets $39.4B $40.7B $44.9B $50B $54.2B
Total Assets $57.6B $57.9B $64.7B $69.1B $78.4B
Current Liabilities $41.6B $44.8B $50.8B $54.5B $59.1B
Total Liabilities $57B $57.8B $63.6B $68.7B $76.3B
Total Equity $601.1M $73.6M $1.1B $361.9M $2.1B
Total Debt $6.7B $5.6B $4.8B $8.1B $7.9B
Trailing 12 Months Fiscal Quarters
Period Ending 2023-12-31 2024-12-31 2025-12-31 2024-12-31 2025-12-31
Cash Flow Statement
Cash Flow Operations $4.1B -$119.3M $4.3B -$2.7B -$2.3B
Cash From Investing -$1.2B -$895.3M -$4.9B -$343M -$299.3M
Cash From Financing -$1.8B $1.4B -$916.8M $3.2B $43.2M
Free Cash Flow $3.6B -$638.1M $3.6B -$2.8B -$2.4B
COR
Sector
Market Cap
$70.2B
$25.5M
Price % of 52-Week High
95.64%
49.47%
Dividend Yield
0.64%
0%
Shareholder Yield
-0%
-1.77%
1-Year Price Total Return
48.31%
-21.96%
Beta (5-Year)
0.676
0.499
Dividend yield:
0.64%
Annualized payout:
$2.20
Payout ratio:
20.94%
Growth streak:
20 years

Technicals

8-day SMA
Buy
Level $359.75
200-day SMA
Buy
Level $318.35
Bollinger Bands (100)
Buy
Level 327.04 - 361.24
Chaikin Money Flow
Sell
Level -2M
20-day SMA
Buy
Level $356.75
Relative Strength Index (RSI14)
Buy
Level 54.33
ADX Line
Sell
Level 19.29
Williams %R
Neutral
Level -29.4582
50-day SMA
Buy
Level $348.81
MACD (12, 26)
Buy
Level 80.50
25-day Aroon Oscillator
Buy
Level 24
On Balance Volume
Neutral
Level 3.9M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.8706)
Sell
CA Score (Annual)
Level (-0.7035)
Buy
Beneish M-Score (Annual)
Level (-2.5377)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.8039)
Buy
Piotroski F Score (Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments. The U.S. Healthcare Solutions segment is involved in the offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a wide variety of healthcare providers. The International Healthcare Solutions segment includes businesses that focus on international pharmaceutical wholesale and related service operations, and global commercialization services. The company was founded by Emil P. Martini in 1947 and is headquartered in Conshohocken, PA.

Stock Forecast FAQ

In the current month, COR has received 10 Buy ratings 3 Hold ratings, and 0 Sell ratings. The COR average analyst price target in the past 3 months is $403.79.

  • Where Will Cencora, Inc. Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Cencora, Inc. share price will rise to $403.79 per share over the next 12 months.

  • What Do Analysts Say About Cencora, Inc.?

    Analysts are divided on their view about Cencora, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cencora, Inc. is a Sell and believe this share price will drop from its current level to $340.00.

  • What Is Cencora, Inc.'s Price Target?

    The price target for Cencora, Inc. over the next 1-year time period is forecast to be $403.79 according to 13 Wall Street analysts, 10 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.

  • Is COR A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Cencora, Inc. is a Buy. 10 of 13 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of COR?

    You can purchase shares of Cencora, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cencora, Inc. shares.

  • What Is The Cencora, Inc. Share Price Today?

    Cencora, Inc. was last trading at $360.89 per share. This represents the most recent stock quote for Cencora, Inc.. Yesterday, Cencora, Inc. closed at $361.08 per share.

  • How To Buy Cencora, Inc. Stock Online?

    In order to purchase Cencora, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Celestica The Best AI Stock to Buy Now?
Is Celestica The Best AI Stock to Buy Now?

Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…

Will AI Disrupt SaaS Software Stocks?
Will AI Disrupt SaaS Software Stocks?

Since January 28th, software stocks in the United States have…

Why Is Meta Stock Going Higher?
Why Is Meta Stock Going Higher?

Over the last five days, shares of Instagram and Facebook…

Stock Ideas

Buy
55
Is NVDA Stock a Buy?

Market Cap: $4.6T
P/E Ratio: 65x

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 35x

Sell
40
Is GOOGL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 29x

Alerts

Buy
77
RNG alert for Feb 21

RingCentral, Inc. [RNG] is up 34.37% over the past day.

Sell
9
FROG alert for Feb 21

JFrog Ltd. [FROG] is down 24.98% over the past day.

Buy
72
SNSE alert for Feb 21

Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock